{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T22:03:01Z","timestamp":1793138581752,"version":"4.5.0"},"reference-count":34,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T00:00:00Z","timestamp":1750982400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"The collaborative Trajectory Analysis Project"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:p>The North Star Ambulatory Assessment (NSAA) is a widely used functional endpoint in drug development for ambulatory patients with Duchenne muscular dystrophy (DMD). Accurately predicting NSAA total score trajectories is important for designing randomized trials for novel therapies in DMD and for contextualizing outcomes, especially over longer-term follow-up (&gt;18 months) when placebo-controlled studies are infeasible. We developed a prognostic model for NSAA total score trajectories over at most 5 years of follow-up for patients with DMD aged 4 to &lt;16 years who were initially ambulatory and receiving corticosteroids but no other disease-modifying therapies. The model was based on longitudinal data from four natural history databases: UZ Leuven, PRO-DMD-01 (provided by CureDuchenne), the North Star Clinical Network, and iMDEX. Candidate predictors included age, height, weight, body mass index, steroid type and regime, NSAA total score, rise from floor velocity, and 10-meter walk\/run velocity, as well as <jats:italic>DMD<\/jats:italic> genotype class, index year, and data source. Among N\u2009=\u2009416 patients at baseline, mean age was 8.2 years, mean NSAA total score was 24, and 61% were receiving prednisone and 39% deflazacort, with the majority having been treated with daily corticosteroid regimens (69%) relative to other regimens (31%). Patients had an average of four NSAA assessments post-baseline during a median follow-up of 2.6 years (inter-quartile range 1.9 to 3.6 years). The best-fitting model in the full study sample explained 39% of the variation in NSAA total score changes, with prediction errors of \u00b13.6, 5.1, 5.9, 7.5, 9.5 NSAA units during follow-up years 1\u20135, respectively. The most important predictors were baseline age, NSAA, rise from floor velocity, and 10-meter walk\/run velocity. In conclusion, trajectories of ambulatory motor function in DMD, as measured by the NSAA total score, can be well-predicted using readily available baseline characteristics. We discuss applications of these predictions to DMD drug development.<\/jats:p>","DOI":"10.1371\/journal.pone.0325736","type":"journal-article","created":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T17:25:26Z","timestamp":1751045126000},"page":"e0325736","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":7,"title":["Predicting trajectories of the north star ambulatory assessment total score in Duchenne muscular dystrophy"],"prefix":"10.1371","volume":"20","author":[{"given":"Francesco","family":"Muntoni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4067-8962","authenticated-orcid":true,"given":"James","family":"Signorovitch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Goemans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adnan Y.","family":"Manzur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolae","family":"Done","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gautam","family":"Sajeev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanane","family":"Akbarnejad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aarushi","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5729-5263","authenticated-orcid":true,"given":"Susan J.","family":"Ward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik H.","family":"Niks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurant","family":"Servais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenio","family":"Mercuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Guglieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volker","family":"Straub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imelda","family":"de Groot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1336-6450","authenticated-orcid":true,"given":"Deborah","family":"Ridout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"PRO-DMD-01 study investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Association Fran\u00e7aise contre les Myopathies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"The NorthStar Clinical Network","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8779-3220","authenticated-orcid":true,"given":"Craig","family":"McDonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2025,6,27]]},"reference":[{"issue":"1","key":"pone.0325736.ref001","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s13023-017-0631-3","article-title":"The burden, epidemiology, costs and treatment for Duchenne muscular dystrophy: an evidence review","volume":"12","author":"S Ryder","year":"2017","journal-title":"Orphanet J Rare Dis"},{"key":"pone.0325736.ref002","doi-asserted-by":"crossref","first-page":"1183101","DOI":"10.3389\/fphys.2023.1183101","article-title":"Duchenne muscular dystrophy: disease mechanism and therapeutic strategies","volume":"14","author":"A Bez Batti Angulski","year":"2023","journal-title":"Front Physiol"},{"issue":"1","key":"pone.0325736.ref003","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s13023-017-0631-3","article-title":"The burden, epidemiology, costs and treatment for Duchenne muscular dystrophy: an evidence review","volume":"12","author":"S Ryder","year":"2017","journal-title":"Orphanet J Rare Dis"},{"issue":"4","key":"pone.0325736.ref004","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S1474-4422(18)30025-5","article-title":"Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management","volume":"17","author":"DJ Birnkrant","year":"2018","journal-title":"Lancet Neurol"},{"issue":"3","key":"pone.0325736.ref005","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S1474-4422(18)30024-3","article-title":"Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management","volume":"17","author":"DJ Birnkrant","year":"2018","journal-title":"Lancet Neurol"},{"issue":"9","key":"pone.0325736.ref006","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.nmd.2016.05.016","article-title":"Categorizing natural history trajectories of ambulatory function measured by the 6-minute walk distance in patients with Duchenne muscular dystrophy","volume":"26","author":"E Mercuri","year":"2016","journal-title":"Neuromuscul Disord"},{"issue":"9","key":"pone.0325736.ref007","article-title":"Categorising trajectories and individual item changes of the North Star Ambulatory Assessment in patients with Duchenne muscular dystrophy","volume":"14","author":"UK NorthStar Network","year":"2019","journal-title":"PLoS One"},{"issue":"1","key":"pone.0325736.ref008","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0895-4356(98)00138-3","article-title":"Stratified randomization for clinical trials","volume":"52","author":"WN Kernan","year":"1999","journal-title":"J Clin Epidemiol"},{"issue":"13","key":"pone.0325736.ref009","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000008168","article-title":"Vamorolone trial in Duchenne muscular dystrophy shows dose-related improvement of muscle function","volume":"93","author":"EP Hoffman","year":"2019","journal-title":"Neurology"},{"issue":"3","key":"pone.0325736.ref010","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1002\/mus.23902","article-title":"The 6-minute walk test and other endpoints in Duchenne muscular dystrophy: longitudinal natural history observations over 48 weeks from a multicenter study","volume":"48","author":"CM McDonald","year":"2013","journal-title":"Muscle Nerve"},{"issue":"7","key":"pone.0325736.ref011","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.nmd.2009.06.368","article-title":"Reliability of the North Star Ambulatory Assessment in a multicentric setting","volume":"19","author":"ES Mazzone","year":"2009","journal-title":"Neuromuscul Disord"},{"issue":"2","key":"pone.0325736.ref012","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/pri.520","article-title":"Development of a functional assessment scale for ambulatory boys with Duchenne muscular dystrophy","volume":"17","author":"E Scott","year":"2012","journal-title":"Physiother Res Int"},{"issue":"2","key":"pone.0325736.ref013","first-page":"149","article-title":"The NorthStar Ambulatory Assessment in Duchenne muscular dystrophy: considerations for the design of clinical trials","volume":"87","author":"V Ricotti","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"6","key":"pone.0325736.ref014","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0218683","article-title":"Long-term natural history data in Duchenne muscular dystrophy ambulant patients with mutations amenable to skip exons 44, 45, 51 and 53","volume":"14","author":"C Brogna","year":"2019","journal-title":"PLoS One"},{"issue":"6","key":"pone.0325736.ref015","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0253882","article-title":"North Star Ambulatory Assessment changes in ambulant Duchenne boys amenable to skip exons 44, 45, 51, and 53: A 3 year follow up","volume":"16","author":"G Coratti","year":"2021","journal-title":"PLoS One"},{"issue":"4","key":"pone.0325736.ref016","article-title":"Disease progression rates in ambulatory Duchenne muscular dystrophy by steroid type, patient age and functional status","volume":"12","author":"CM McDonald","year":"2023","journal-title":"J Comp Eff Res"},{"issue":"10","key":"pone.0325736.ref017","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0108205","article-title":"Long term natural history data in ambulant boys with Duchenne muscular dystrophy: 36-month changes","volume":"9","author":"M Pane","year":"2014","journal-title":"PLoS One"},{"issue":"10","key":"pone.0325736.ref018","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0164684","article-title":"Individualized prediction of changes in 6-minute walk distance for patients with\u00a0Duchenne\u00a0muscular dystrophy","volume":"11","author":"N Goemans","year":"2016","journal-title":"PLoS One"},{"issue":"6","key":"pone.0325736.ref019","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0232870","article-title":"Prognostic factors for changes in the timed 4-stair climb in patients with Duchenne muscular dystrophy, and implications for measuring drug efficacy: A multi-institutional collaboration","volume":"15","author":"N Goemans","year":"2020","journal-title":"PLoS One"},{"key":"pone.0325736.ref020","doi-asserted-by":"crossref","DOI":"10.1016\/j.jval.2019.09.2456","article-title":"PRO126 A composite prognostic score for time to loss of walking ability in Duchenne Muscular Dystrophy (DMD)","volume":"22","author":"N Goemans","year":"2019","journal-title":"Value in Health"},{"issue":"8","key":"pone.0325736.ref021","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1111\/dmcn.15176","article-title":"Peak functional ability and age at loss of ambulation in Duchenne muscular dystrophy","volume":"64","author":"AA Zambon","year":"2022","journal-title":"Dev Med Child Neurol"},{"issue":"4","key":"pone.0325736.ref022","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.nmd.2022.02.009","article-title":"Real-world and natural history data for drug evaluation in Duchenne muscular dystrophy: suitability of the North Star Ambulatory Assessment for comparisons with external controls","volume":"32","author":"F Muntoni","year":"2022","journal-title":"Neuromuscul Disord"},{"issue":"15","key":"pone.0325736.ref023","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000201626","article-title":"DMD Genotypes and Motor Function in Duchenne Muscular Dystrophy: A Multi-institution Meta-analysis With Implications for Clinical Trials","volume":"100","author":"F Muntoni","year":"2023","journal-title":"Neurology"},{"key":"pone.0325736.ref024","doi-asserted-by":"crossref","unstructured":"Muntoni F, Signorovitch J, Goemans N, Manzur A, Done N, Sajeev G, et al. Predicting Trajectories of Ambulatory Function in Duchenne Muscular Dystrophy. Poster presented at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference. March 13-16, 2022; Nashville, TN.","DOI":"10.1212\/WNL.98.18_supplement.1691"},{"issue":"3","key":"pone.0325736.ref025","article-title":"mice: Multivariate Imputation by Chained Equations inR","volume":"45","author":"S van Buuren","year":"2011","journal-title":"J Stat Soft"},{"issue":"1","key":"pone.0325736.ref026","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1186\/s12874-018-0615-6","article-title":"A comparison of multiple imputation methods for missing data in longitudinal studies","volume":"18","author":"MH Huque","year":"2018","journal-title":"BMC Med Res Methodol"},{"issue":"6","key":"pone.0325736.ref027","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1080\/00949655.2012.741599","article-title":"Mixed-effects random forest for clustered data","volume":"84","author":"A Hajjem","year":"2012","journal-title":"J Stat Comput Simulation"},{"key":"pone.0325736.ref028","volume-title":"Adjusting for covariates in randomized clinical trials for drugs and biological products: guidance for industry","author":"FDA U","year":"2023"},{"key":"pone.0325736.ref029","volume-title":"Considerations for the design and conduct of externally controlled trials for drug and biological products: guidance for industry","author":"FDA U","year":"2023"},{"issue":"8","key":"pone.0325736.ref030","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1001\/jama.2017.9991","article-title":"Multidimensional evidence generation and FDA regulatory decision making: defining and using \u201creal-world\u201d data","volume":"318","author":"JP Jarow","year":"2017","journal-title":"JAMA"},{"issue":"15","key":"pone.0325736.ref031","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1001\/jama.2022.4315","article-title":"Effect of different corticosteroid dosing regimens on clinical outcomes in boys with\u00a0Duchenne\u00a0muscular dystrophy: a randomized clinical trial","volume":"327","author":"M Guglieri","year":"2022","journal-title":"JAMA"},{"issue":"3","key":"pone.0325736.ref032","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/psp4.12753","article-title":"Development of a model-based clinical trial simulation platform to optimize the design of clinical trials for Duchenne muscular dystrophy","volume":"11","author":"K Lingineni","year":"2022","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"pone.0325736.ref033","article-title":"Meaningful changes in motor function in Duchenne muscular dystrophy (DMD): a multi-center study","author":"a Muntoni F e","year":"2024","journal-title":"PLoS One"},{"key":"pone.0325736.ref034","volume-title":"Duchenne Muscular Dystrophy and Related Dystrophinopathies: Developing Drugs for Treatment","author":"FDA U","year":"2018"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0325736","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T17:25:41Z","timestamp":1751045141000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0325736"}},"subtitle":[],"editor":[{"given":"Hyojung","family":"Choo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,6,27]]},"references-count":34,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,6,27]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0325736","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,27]]}}}